Pelacarsen (TQJ230)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
May 19, 2025 → Dec 8, 2030
NCT ID
NCT06875973About Pelacarsen (TQJ230)
Pelacarsen (TQJ230) is a phase 3 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06875973. Target conditions include Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06875973 | Phase 3 | Recruiting |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease